Two institutional buyers of Gleevec want to stop its manufacturer, Novartis, from delaying generic competition of the blockbuster leukemia drug, saying a patent litigation settlement between the brandmaker and generics maker Sun Pharma ...
Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by...
In my view, the market is set to crash at a certain point in the future. The reason? If the FED...
A drug manufacturer is asking the Mississippi Supreme Court to reverse a $38.2 million judgment for the state in a Medicaid drug-pricing lawsuit.
Botox maker Allergan Plc. is buying Kythera Biopharmaceuticals for about $2.1 billion, adding a drug that destroys fat cells and eliminates the cosmetic condition referred to as "double chin".
ITP affects as many as 5 in 100,000 children each year and is characterized by a low platelet count.
Carna Biosciences today announced a worldwide licensing agreement with Janssen Biotech to further develop and commercialize compounds from one of Carna Bioscience’s small molecule protein kinase inhibitor programs.
It's the healthcare giant's first project under its ambitious initiative to prevent or at least intercept and reduce harm from many diseases.
Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with the caveat that more data is needed about its long-term ability to reduce heart attacks.
The project will create a new forum for collaborative analysis of Janssen's clinical trial data with data available from the National Institutes of Health (NIH) about schizophrenia.
A $6 million gift from Janssen Pharmaceuticals will help spur Rutgers’ research into “revolutionary” continuous manufacturing.
Promising trial results for a new drug designed to treat aggressive breast cancer helped Pfizer double its share of that market, according to CEO Ian Read.
The drug — named brodalumab — led to suicidal thoughts among trial patients, which could result in regulators attaching a warning label to the product.
Perrigo will acquire a portfolio of well-established over-the-counter brands from GlaxoSmithKline Consumer Healthcare.
Senior leaders announced plans to file for regulatory approval of more than 10 new products between 2015 and 2019.
The company’s other operations, including health care and crop science, are in the midst of an overhaul as Bayer transitions to a “pure life-sciences company."
Federal regulators announced Thursday that Teva Pharmaceuticals will pay $1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil.
The multi-year program, which will award a total of up to $3 million in grants to investigators in the United States, is an extension of Pfizer’s Advancing Science through Pfizer Investigator Research Exchange initiative.
Under the agreement, Ventana will develop an in vitro diagnostic using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval. The target will be metastatic pancreatic cancer patients.
Data will demonstrate advances in research in a variety of cancer types, including melanoma, lung, breast, kidney and blood cancers. The goal of these products will be to improve and possibly extend the lives of people with solid and hematologic tumors.
US Pharma M&A activity has yet to show any signs of a slowdown after the $8.1bn exit of Par Pharma by TPG to Endo was announced on Monday. The US Pharma industry has seen 39 deals valued at US$ 77.3bn to-date, three more deals announced ...
Today, Novartis announced for the first time detailed results from its phase III EXPEDITION trial program for QVA149 (indacaterol/glycopyrronium) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In the US ...
At a meeting today with analysts, Johnson & Johnson's Janssen Pharmaceuticals announced plans for regulatory approval of more than 10 new drugs between 2015 and 2019, each with the potential to generate at least $1B in sales, in addition to ...
Pfizer Inc. is trying to overcome the patent cliff that has seen its recent quarter results suffer by adopting its classic strategy of forging marketing alliances and making acquisitions. The pharma giant recently agreed to buy a stake in Dutch biotechnology company AM-Pharma....
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has amended a previously granted Breakthrough Therapy Designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C (HCV) patients.
Three years ago a jury found that a subsidiary, Janssen Pharmaceutical, committed Medicaid fraud and violated a state law in its labeling and marketing of Risperdal. A $1.2 billion fine was initially imposed on Johnson & Johnson.
Eagle Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. Patent No. 9,034,908, which pertains to the use of the bendamustine hydrochloride (HCl) formulation administered in a 50mL bag within ten minutes.
Pfizer Inc. today announced that it has received a request for additional information from the FTC with respect to its previously announced proposed acquisition of Hospira.
- Page 1